Worldwide CRISPR Industry to 2028 - by Application, End-user and Region


Dublin, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2022-2028" report has been added to's offering.

The global CRISPR market is anticipated to grow at a substantial CAGR of 36.8 % during the forecast period. The growing age-related disorders, increasing prevalence of lifestyle-oriented diseases and fatalities, and growing drug discovery market are also expected to be the key factors that are driving the growth of the market.

However, there are certain factors that are hampering the growth of the market. Patent infringement and ethical issues associated with the misuse of CRISPR gene editing tools are estimated to hamper the growth of the market.

The global CRISPR market is segmented based on the application and end-user. Based on the application, the market is segmented into cell line engineering, CRISPR plasmid, gene database/gene library, genetic engineering, genetically modified organism or crops, genome editing, and human stem cells. Based on the end-user, the market is sub-segmented into academic institutes, biotechnology companies, pharmaceutical companies, and research and development institutes.

The above-mentioned segments can be customized as per the requirements. Among application segments, the CRISPR plasmid is expected to hold a prominent share in the market over the forecast period. The CRISPR-Cas9 system offers over other mutagenic techniques like ZFN and TALEN is the relative simplicity of its plasmid design and construction, which supports the segment growth positively during the forecast period.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a significant share in the market during the forecast period. Several advancements in CRISPR technology by players in the region are propelling the growth of the market. The advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies, and more.

The major companies serving the global CRISPR market include Caribou Bioscience Inc., Collects SA, Crispr Therapeutics AG, Editas Medicine, Inc., Genscript Biotech Corp., Horizon Discovery Ltd., Lonza Group Ltd., Merck KGaA, Darmstadt, Origene Technologies, and others.

The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.

The Report Covers

  • Comprehensive research methodology of the global CRISPR market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global CRISPR market.
  • Insights about market determinants that are stimulating the global CRISPR market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players

4. Market Segmentation
4.1. Global CRISPR Market by Application
4.1.1. Cell Line Engineering
4.1.2. CRISPR Plasmid
4.1.3. Gene Database/Gene Library
4.1.4. Genetic Engineering
4.1.5. Genetically Modified Organism or Crops
4.1.6. Genome Editing
4.1.7. Human Stem Cells
4.2. Global CRISPR Market by End-User
4.2.1. Academic Institutes
4.2.2. Biotechnology Companies
4.2.3. Pharmaceuticals Companies
4.2.4. Research and Development Institutes

5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles
6.1. Addgene
6.2. AstraZeneca PLC
6.3. Bio-Rad Laboratories, Inc.
6.4. Caribou Bioscience Inc.
6.5. Cellectics SA
6.6. Crispr Therapeutics AG
6.7. Editas Medicine, Inc.
6.8. Genscript Biotech Corp.
6.9. Horizon Discovery Ltd.
6.10. Integrated DNA Technologies, Inc.
6.11. Intellia Therapeutics Inc.
6.12. Lonza Group Ltd.
6.13. Merck KGaA, Darmstadt
6.14. Origene Technologies, Inc.
6.15. Precision Bioscience, Inc.
6.16. Sangamo Therapeutics Inc.
6.17. Thermo Fisher Scientific
6.18. Transposagen Biopharmaceuticals, Inc.

For more information about this report visit